These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 25834406)

  • 21. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
    Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
    Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study.
    Lojanapiwat B; Permpongkosol S
    Int Braz J Urol; 2011; 37(4):468-76. PubMed ID: 21888698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
    Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
    Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
    Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
    Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin.
    Yang PS; Chen CL; Hou CP; Lin YH; Tsui KH
    Clin Interv Aging; 2018; 13():235-242. PubMed ID: 29445269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
    Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
    Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS™ for up to 1 year in adult men with both storage and voiding LUTS: A subanalysis of the NEPTUNE/NEPTUNE II randomized controlled studies.
    Drake MJ; Oelke M; Snijder R; Klaver M; Traudtner K; van Charldorp K; Bongaerts D; Van Kerrebroeck P
    PLoS One; 2017; 12(2):e0170726. PubMed ID: 28166296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The combined symptoms of male lower urinary tract: current treatment options].
    Gadzhieva ZK; Gazimiev MA; Kazilov YB; Grigoryan VA
    Urologiia; 2018 Oct; (4):135-141. PubMed ID: 30761804
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower urinary tract symptoms associated with benign prostatic hyperplasia: combined treatment with fesoterodine fumarate extended-release and tamsulosin--a prospective study.
    Konstantinidis C; Samarinas M; Andreadakis S; Xanthis S; Skriapas K
    Urol Int; 2013; 90(2):156-60. PubMed ID: 23221480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Crossover Comparison of the Short-Term Efficacy and Safety of Single Half-Dose Silodosin and Tamsulosin Hydrochoride in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
    Takeshita H; Moriyama S; Arai Y; Washino S; Saito K; Chiba K; Horiuchi S; Noro A
    Low Urin Tract Symptoms; 2016 Jan; 8(1):38-43. PubMed ID: 26789541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
    Barkin J; Diles D; Franks B; Berner T
    Can J Urol; 2015 Aug; 22(4):7914-23. PubMed ID: 26267031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tamsulosin Treatment Affecting Patient-reported Outcomes in Benign Prostatic Hyperplasia-associated Depressive Symptoms.
    Kim KS; Jang EY; Kim YT; Moon HS
    Urology; 2016 Jan; 87():172-7. PubMed ID: 26525959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effective tool for self-assessment of adherence to treatment in patients with benign prostatic obstruction and overactive bladder symptoms.
    Kosilov K; Loparev S; Kuzina I; Shakirova O; Zhuravskaya N; Lobodenko A
    Aging Male; 2017 Mar; 20(1):39-44. PubMed ID: 28074677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effectiveness of Omnic and Omnic Ocas in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia (multi-center observing program)].
    Shalekenov BU; Kuandykov YA; Shalekenov SB
    Urologiia; 2017 Oct; (5):42-47. PubMed ID: 29135141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study.
    Oelke M; Giuliano F; Baygani SK; Melby T; Sontag A
    BJU Int; 2014 Oct; 114(4):568-75. PubMed ID: 24612148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.